Success of monoclonal antibodies has encouraged researchers to discover and develop next-generation of antibodies. Next-generation antibody therapeutics are improved antibody therapeutics that are highly efficient, offer greater safety, and are easier to deliver. Globally, the next-generation antibody therapeutics market is witnessing significant growth due to growing R&D activities, increasing prevalence of chronic diseases, and technological advancements in antibody therapeutics. In addition, increasing healthcare expenditure is also driving growth of the global next-generation antibody therapeutics market. However, factors such as high costs of next generation antibody therapeutics, stringent regulatory requirements, and long approval time are restraining growth of the market. The global next-generation antibody therapeutics market is projected to be valued at US$ 2,250.0 Mn by the end of 2015. It is likely to grow at a CAGR of 13.0% to account for US$ 6,761.1 Mn by 2022.
